New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus

Decision modeling study shows use of TissueCypher can nearly double appropriate escalation of care for patients with non-dysplastic Barrett's esophagus who later progress to cancer, while substantially reducing overuse of procedures in patients who do not progress FRIENDSWOOD, Texas, Sept. 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new decision modeling study showing that the TissueCypher® Barrett's Esophagus test (TSP-9) can help better align Barrett's esophagus (BE) management with a patient's individual risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC).

PRNewsWire • Sep 15, 2026

JAAD Publication Shows Improved Performance of DecisionDx®-SCC

DecisionDx-SCC shows enhanced performance with the integration of select clinicopathologic risk factors, providing a more precise result to support risk-aligned patient management DecisionDx-SCC's Class 1A (low risk) result demonstrated a 97.3% negative predictive value, supporting confidence in de-escalation decisions, while its Class 2B (highest risk) result identified patients most likely to benefit from adjuvant radiation therapy FRIENDSWOOD, Texas, Sept. 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a multi-center study in the Journal of the American Academy of Dermatology (JAAD) validating the integrated DecisionDx-SCC test result (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma (SCC).1 DecisionDx-SCC analyzes 40 genes to provide results related to prognosis and response to adjuvant radiation therapy (ART) based on an individual patient's tumor biology.

PRNewsWire • Sep 9, 2026

SciBase receives additional order from Castle Biosciences, advancing the collaboration

STOCKHOLM, Sept. 8, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received an additional order for an acceleration of the current, ongoing clinical study and preparations for a second clinical study under the collaboration with Castle Biosciences.

PRNewsWire • Sep 8, 2026

Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know

Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Aug 28, 2026

Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?

The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Aug 25, 2026

Castle Biosciences to Participate in Upcoming Investor Conferences

FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m.

PRNewsWire • Aug 20, 2026

Castle Biosciences Approved for Dual Listing on Nasdaq Texas

FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. Castle will maintain its primary listing on The Nasdaq Global Market, and its common stock is expected to begin listing on Nasdaq Texas today under its existing ticker symbol, "CSTL.

PRNewsWire • Aug 17, 2026

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction

Castle Biosciences NASDAQ: CSTL reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its reported beat, according to CFO Frank Stokes.

MarketBeat • Aug 13, 2026

Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 31, 2026

Castle Biosciences Q2 Earnings Call Highlights

Castle Biosciences NASDAQ: CSTL reported second-quarter 2026 revenue of $103.5 million, up 20% from the prior-year period, as growth in its TissueCypher test and other core offerings supported results. The company raised its full-year revenue outlook to $365 million to $375 million, from a previous range of $345 million to $355 million.

MarketBeat • Jul 30, 2026